<DOC>
	<DOCNO>NCT00615433</DOCNO>
	<brief_summary>Lurasidone HCl compound develop treatment schizophrenia . This clinical study design test hypothesis lurasidone efficacious placebo . The study also evaluate safety tolerability lurasidone compare placebo .</brief_summary>
	<brief_title>Lurasidone HCl A Phase 3 Study Patients With Acute Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Provide write informed consent age 18 75 year age . Meets DSMIV criterion primary diagnosis schizophrenia . Not pregnant , reproductive potential agrees remain abstinent use adequate reliable contraception duration study . Able agrees remain prior antipsychotic medication duration study . Good physical health basis medical history , physical examination , laboratory screening . Willing able comply protocol , include inpatient requirement outpatient visit . Considered investigator imminent risk suicide injury self , others property . Any chronic organic disease CNS ( schizophrenia ) . Used investigational compound within 30 day . Clinically significant history alcohol abuse/alcoholism drug abuse/dependence within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>